eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
07/29/20
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
06/30/20
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
06/11/20
Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020  and Change to a Virtual Meeting Format
Upcoming Events
Date Title
Wednesday, August 12, 2020 4:30 PM EDT